Alpha-1 Antitrypsin for COPD exacerbations in hospital
Part of Lungs & breathing clinical trials.
This trial tests a medicine called alpha-1 antitrypsin given through an IV to people hospitalized with a serious COPD exacerbation. The goal is to see if it helps them recover faster.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 40 years old or older.
- You have a prior diagnosis of COPD confirmed by a breathing test.
- You are currently hospitalized for a moderate to severe COPD flare-up.
- You have low oxygen levels (below 92% on room air) or need more oxygen than usual.
- You have a positive test for a specific protein in your sputum (phlegm).
- You do not have other significant lung diseases, active cancer, or certain immune conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks how safe a prescribed blood protein medicine (alpha-1 proteinase inhibitor) is over the long term in people with Alpha-1 antitrypsin deficiency. You may join if you already finished an earlier study or if your lung function has been declining.
This trial tests a new way to diagnose and treat chronic obstructive pulmonary disease (COPD) flare-ups (sudden worsening of symptoms). It aims to help people who come to the emergency room with a COPD flare-up get better care and follow-up.
This study is looking at people with a specific mild form of alpha-1 antitrypsin deficiency (PiMZ) to understand how their lung disease progresses over time. It involves lung function tests and CT scans, and may help researchers learn more about the condition.
This trial tests a new treatment called BEAM-302, which aims to correct the genetic defect that causes alpha-1 antitrypsin deficiency. It may help prevent further lung and liver damage in people with the PiZZ mutation.
This trial tests an inhaled medication called treprostinil (Tyvaso) to see if it can help people with COPD who have low blood oxygen levels. You may qualify if you have chronic bronchitis, use oxygen at rest or during exercise, and meet specific lung function criteria.
This study tests a new gene therapy called KB408 for people with alpha-1 antitrypsin deficiency (AATD). It aims to see if KB408 can help your body produce enough of the missing protein to protect your lungs and liver.
Hear when a new Acute Exacerbation Chronic Obstructive Pulmonary Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.